# To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)

> **NCT05060523** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 220 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Tolvaptan Tablets
- **DRUG:** Midodrine Oral Tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05060523
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-19
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2021-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060523, "To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05060523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*